Valentin Fuster
Valentin Fuster
Direct-to-Patient Prescription Drug Platforms: What Should Cardiologists Know? [0.03%]
面向患者的处方药平台：心脏病专家需要了解什么？
Kavya M Shah,Kushal T Kadakia,Dhruv S Kazi et al.
Kavya M Shah et al.
Harlan M Krumholz
Harlan M Krumholz
Arnold H Seto,Gautam Kumar,Morton J Kern
Arnold H Seto
Angiographic Quantitative Flow Ratio-Guided Coronary Intervention: 5-Year Follow-Up From the FAVOR III China Randomized Trial [0.03%]
基于中国冠状动脉介入治疗的FAVOR III随机试验五年随访：血管内定量血流分数指导冠脉介入治疗
Han Zhang,Changdong Guan,Zening Jin et al.
Han Zhang et al.
Background: The multicenter, randomized, sham-controlled FAVOR III China trial (Comparison of Quantitative Flow Ratio-Guided and Angiography-Guided Percutaneous Intervention in Patients with Coronary Artery Disease) demon...
What E.B. Meant to Me [0.03%]
E.B.曾对我意味着什么
Douglas L Mann
Douglas L Mann
2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines [0.03%]
2026 AHA/ACC/ADA/ASN心血管-肾脏-代谢综合征的预防、检测、评估和管理指南：美国心脏病学会/美国心脏协会联合临床实践指南小组报告
Chiadi E Ndumele,Fatima Rodriguez,Dave L Dixon et al.
Chiadi E Ndumele et al.
Aim: The "2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome" retires, replaces, and expands upon the "2013 AHA/ACC/TOS Guideline for the M...